Myelodysplastic Syndromes and Myeloproliferative Neoplasms

Rami S. Komrokji MD and Jamile Shammo MD FASCP FACP review data from key MDS and MPN presentations at the 2016 American Society of Hematology Annual Meeting.

Share

Program Content

Activities

  • EPO Sensitivity in LR MDS
    Lenalidomide + Epoetin alfa Restores Erythropoietin Sensitivity in Patients With Lower-Risk Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • Low-Dose HMAs in LR MDS
    Low-Dose Hypomethylating Agents Active, Safe in Low- and Intermediate-1–Risk MDS
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • Enasidenib in m<i>IDH2</i> MDS
    Enasidenib Active, Well Tolerated in Small Cohort of MDS Patients With IDH2 Mutation
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 06, 2016

    Expires: December 05, 2017

  • RUX + AZA in Myelofibrosis
    Ruxolitinib + Azacitidine in Newly Diagnosed or R/R, Intermediate- or High-Risk Myelofibrosis
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 07, 2016

    Expires: December 06, 2017

  • Sotatercept in MPN-Associated Anemia
    Sotatercept Active in Patients With Myeloproliferative Neoplasm–Associated Anemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 08, 2016

    Expires: December 07, 2017

  • Downloadable Slideset
    Myelodysplastic Syndrome and Myeloproliferative Neoplasms
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

    Released: December 19, 2016

    Expires: December 18, 2017

  • NIVO or IPI ± AZA in MDS
    Nivolumab or Ipilimumab ± Azacitidine in Treatment-Naive or HMA-Failed Myelodysplastic Syndromes
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • MPD-RC 112: PegIFN α-2a vs HU in PV/ET
    MPD-RC 112: Frontline Peginterferon α-2a vs Hydroxyurea in High-Risk Polycythemia Vera and Essential Thrombocythemia
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022
  • Ropeginterferon α-2b vs HU in PV
    Phase III PROUD-PV: Ropeginterferon α-2b Noninferior to Hydroxyurea in Polycythemia Vera
    Conference Coverage
    Slideset Download
    Congratulations: You achieved a completion on 04/09/2022

Provided by

ProCE Banner

Supporters

Amgen, Inc.

Celgene

Incyte

Merck & Co., Inc.

Seagen